[1]王朝辉,蒋昌松,聂曼玲,等.国家组织药品集中采购政策对抗乳腺癌药品使用的影响研究[J].卫生经济研究,2025,42(04):37-41.
　WANG Chaohui,JIANG Changsong,NIE Manling,et al.mpact of National Centralized Volume-based Procurement Policy on the Use of Anti-breast Cancer Drugs[J].Journal Press of Health Economics Research,2025,42(04):37-41.
点击复制

国家组织药品集中采购政策对抗乳腺癌药品使用的影响研究
分享到：

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
42
期数:
2025年04期
页码:
37-41
栏目:
药械管理
出版日期:
2025-04-02

文章信息/Info

Title:
mpact of National Centralized Volume-based Procurement Policy on the Use of Anti-breast Cancer Drugs
作者:
王朝辉1; 2; 蒋昌松3; 聂曼玲1; 2; 3; 祁 鹏3; 郭 丹3; 李 娜3; 蒋 婷3; 潘 杰1; 2
1.四川大学华西公共卫生学院/华西第四医院，四川 成都 610041
2.四川大学健康城市发展研究中心/西部农村卫生发展研究中心， 四川 成都 610041
3.首都医科大学国家医疗保障研究院，北京 100037
Author(s):
WANG Chaohui;  JIANG Changsong;  NIE Manling;  Qi Peng;  GUO Dan;  LI Na;  JIANG Ting;  PAN Jie
West China School of Public Health, Sichuan University / West China Fourth Hospital, Chengdu Sichuan 610041, China
关键词:
药品集采; 中选药品; 医疗机构等级; 抗乳腺癌药品
Keywords:
centralized volume-based procurement of drugs;  selected drugs;  medical institution level;  anti-breast cancer drugs
分类号:
R95
文献标志码:
A
摘要:
目的：分析国家组织药品集中采购政策对抗乳腺癌药品使用的影响。方法：基于样本市2019—2022年公立医院药品采购数据，选取7种抗乳腺癌集采药品作为研究对象，采用间断时间序列分析法，分析政策执行前后药品采购量、采购金额、日均费用和中选药品用量占比的变化，并按医疗机构等级和药品药理类别进行分层分析。结果：集采政策实施后，集采品种尤其是中选药品的采购量显著提升，中选药品用量占比从4.39%增长至56.39%；药品采购金额和日均费用明显降低，二级医院中选药品用量占比显著高于三级医院，紫杉烷类药品的中选药品用量占比显著高于其他药理类。结论：集采政策有效促进了中选药品的使用，降低了患者用药负担，但政策实施过程中容易忽视药品使用存在差异的实际情况；建议实施精细化管理，设置统一的医保支付标准，促进中选药品的合理优先使用。
Abstract:
Objective To analyze impact of national centralized volume-based procurement policy on the use of anti-breast cancer drugs. Methods Based on the 2019-2022 drug procurement data of public hospitals in the sample city, seven anti-breast cancer drugs in centralized volume-based procurement were selected as research objects. Interrupted time series analysis was used to analyze the changes in the procurement volume, procurement amount, average daily cost, and percentage of the usage of the selected drugs before and after the implementation of the policy, and stratified by the level of medical institutions and pharmacological categories of drugs. Results After the implementation of centralized volume-based procurement policy, the procurement volume of centralized volume-based procurement varieties, especially the selected drugs, was significantly increased, and the proportion of the usage of selected drugs grew from 4.39% to 56.39%. The procurement amount of drugs and the average daily cost were significantly reduced, and the proportion of the usage of selected drugs in second-level hospitals was significantly higher than that in third-level hospitals. The proportion of selected drugs in taxanes was significantly higher than that of other pharmacological drugs. Conclusion The centralized volume-based procurement policy effectively promotes the use of selected drugs and reduces the drug burden on patients. However, the actual situation of differences in drug use is ignored during policy implementation. It is recommended to implement refined management, and set medical insurance payment standards, so as to promote the reasonable and priority use of selected drugs.

参考文献/References:

[1] 蒋昌松，张立强，祁鹏，等.带量采购的部分经济学原理解析[J]. 卫生经济研究，2021，38（06）：63-65.
[2] Zhao B,Wu J.Impact of China’s national volume-based procurement on drug procurement price,volume, and expenditure:an Interrupted time series analysis in Tianjin[J].International Journal of Health Policy and Management,2023,12:7724.
[3] Wang J,Yang Y,Xu L,et al.Impact of “4+7” volume-based drug procurement on the use of policy-related original and generic drugs: a natural experimental study in China[J].BMJ Open,2022,12(03): e054346.
[4] 国家医疗保障局.关于国家组织药品集中采购和使用试点医保配套措施的意见[EB/OL]. （2019）[2024-06-06].https://www.gov.cn/zhengce/zhengceku/2019-10/12/content_5438741.htm.
[5] 徐源，金春林，宋捷，等.精神类药品集中带量采购的执行现状与政策优化[J].卫生经济研究，2024，41（06）：34-38.
[6] Han B,Zheng R,Zeng H,et al.Cancer incidence and mortality in China,2022[J].Journal of the National Cancer Center,2024,4(01): 47-53.
[7] World Health Organization.Breast cancer[EB/OL].（2024-03-13）[2024-10-14].https://www.who.int/news-room/fact-sheets/detail/breast-cancer.
[8] Yuan J,Lu Z K,Xiong X,et al.Lowering drug prices and enhancing pharmaceutical affordability: an analysis of the national volume-based procurement(NVBP) effect in China[J].BMJ Global Health,2021,6(09):e005519.
[9] 韩亚进，赵紫楠，李可欣，等.基于国家药品集中带量采购政策的北京市抗肿瘤靶向药物的可负担性评价[J].临床药物治疗杂志，2024，22（07）：23-28.
[10] 国家卫生健康委办公厅关于印发肿瘤和血液病相关病种诊疗指南（2022年版）的通知[EB/OL]. （2022-04-11）[2024-10-14]. http://www.nhc.gov.cn/yzygj/s2911/202204/a0e67177df1f43 9898683e1333957c74.shtml.
[11] 马枋婷，常峰，路云，等.我国药品集中带量采购政策执行情况分析[J].卫生经济研究，2023，40（07）：17-19,24.
[12] 王浩扬，韩悦，谢金平，等.国家药品集中带量采购及接续政策对药品用量、价格及费用的影响研究[J].中国卫生经济，2024，43（10）：31-37.
[13] 何璐璐，金朝辉，郑明琳，等.国家组织药品集中带量采购对某院口服降糖药使用的影响及思考[J].中国药业，2023，32（08）：9-12.
[14] 李梦龙，杨佳.推进分级诊疗制度背景下北京市不同级别医院患者就医选择行为研究[J].中国医院，2018，22（03）：1-4.
[15] 林爱华，柳青.广东省各级医院就诊病人疾病构成分析[J].中国医院统计，2000（03）：138-140.
[16] SHINE.An analysis on the mediating effect of price sensitivity and disease severity between risk perception and intention to use of AI medical system[J]. ??????? ,2021,15(02):75-89.
[17] 陈缪丰，谢金平，王斌，等.常州市各级医院带量采购政策实施效果差异研究[J].中国卫生资源，2022，25（06）：765-769，779.
[18] Zhao M,Nie P,Wu J.Heterogeneity in price elasticity of medicine demand in Ｃhina:moderate effect from economic incentive and quality difference[J].Frontiers in Pharmacology,2021,12: 688069.
[19] 李新刚，赵志刚.从临床疗效角度谈原研药和仿制药的区别[J].药品评价，2013，10（12）：8-12，21.
[20] 陈昊，饶苑弘.新时代的药品带量采购实践与思考[J].中国药物经济学，2019，14（07）：19-26.
[21] 杜雪，马珺，黎雯霞.药品带量采购存在的问题与对策分析[J]. 卫生经济研究，2020，37（08）：42-44, 49.
[22] 王琳宁，路云.日本“价格带”汇总的医保支付标准调整方式及启示[J].中国医疗保险，2023（02）：12-18.
[23] 李孜，刘宇刚，陈偲演，等.德国参考定价制度对我国非独家药品医保支付标准的启示[J].中国医疗保险，2023（03）：48-52.

相似文献/References:

[1]周菁菁,谈在祥.我国药品带量采购政策实施效果研究——以S医院为例[J].卫生经济研究,2021,38(10):52.
　ZHOU Jing-jing,TAN Zai-xiang.Research on the Implementation Effect of Drug Volume Purchasing Policy in China——Taking S Hospital as an Example[J].Journal Press of Health Economics Research,2021,38(04):52.
[2]王 彪,廖 鹏,唐啸宇,等.国家集中带量采购中选药品的供应短缺问题研究[J].卫生经济研究,2024,41(02):40.
　WANG Biao,LIAO Peng,TANG Xiaoyu,et al.Study on the Supply Shortage of Selected Drugs in National Centralized Volume-based Procurement[J].Journal Press of Health Economics Research,2024,41(04):40.
[3]仇晓坤,陈珉惺,吴卿仪,等.基于长三角联盟国采接续的综合评价指标体系研究[J].卫生经济研究,2024,41(08):1.
　QIU Xiaokun,CHEN Minxing,WU Qingyi,et al.Study on the Comprehensive Evaluation Index System based on the Continuation of National Centralized Procurement of Drugs in the Yangtze River Delta Alliance[J].Journal Press of Health Economics Research,2024,41(04):1.

更新日期/Last Update: 2025-04-02